Drug intelligence / Profile preview

DPX-102

Development stage: Preclinical
Lead developer: DAMONA Pharmaceuticals
Modality: Small Molecules

Overview

DPX-102 is a small molecule chemical drug developed by Damona Pharmaceuticals. It acts as a modulator of specific subtypes of the gamma-aminobutyric acid A (GABA-A) receptor, specifically targeting the alpha-2 (GABRA2), alpha-3 (GABRA3), and alpha-5 (GABRA5) subunits. By modulating these GABA-A receptor subtypes, DPX-102 aims to restore impaired inhibitory neurotransmission in the brain, which is implicated in various nervous system disorders. The drug is being investigated for its potential use in treating epilepsy and generalized anxiety disorder. As of June 2024, it remains in preclinical development[1][2][4].

Targets

GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)GABRA5 (Gamma-aminobutyric acid type A receptor subunit alpha-5)GABRA3 (Gamma-aminobutyric acid receptor subunit alpha-3)

Beyond the preview

Go deeper on DPX-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DPX-102.

Explore the full profile